PMID- 35697299 OWN - NLM STAT- MEDLINE DCOM- 20220707 LR - 20220713 IS - 1532-8600 (Electronic) IS - 0026-0495 (Linking) VI - 133 DP - 2022 Aug TI - TCF7L2 plays a complex role in human adipose progenitor biology, which might contribute to genetic susceptibility to type 2 diabetes. PG - 155240 LID - S0026-0495(22)00118-4 [pii] LID - 10.1016/j.metabol.2022.155240 [doi] AB - INTRODUCTION: Non-coding genetic variation at TCF7L2 is the strongest genetic determinant of type 2 diabetes (T2D) risk in humans. TCF7L2 encodes a transcription factor mediating the nuclear effects of WNT signaling in adipose tissue (AT). In vivo studies in transgenic mice have highlighted important roles for TCF7L2 in adipose tissue biology and systemic metabolism. OBJECTIVE: To map the expression of TCF7L2 in human AT, examine its role in human adipose cell biology in vitro, and investigate the effects of the fine-mapped T2D-risk allele at rs7903146 on AT morphology and TCF7L2 expression. METHODS: Ex vivo gene expression studies of TCF7L2 in whole and fractionated human AT. In vitro TCF7L2 gain- and/or loss-of-function studies in primary and immortalized human adipose progenitor cells (APCs) and mature adipocytes (mADs). AT phenotyping of rs7903146 T2D-risk variant carriers and matched controls. RESULTS: Adipose progenitors (APs) exhibited the highest TCF7L2 mRNA abundance compared to mature adipocytes and adipose-derived endothelial cells. Obesity was associated with reduced TCF7L2 transcript levels in whole subcutaneous abdominal AT but paradoxically increased expression in APs. In functional studies, TCF7L2 knockdown (KD) in abdominal APs led to dose-dependent activation of WNT/beta-catenin signaling, impaired proliferation and dose-dependent effects on adipogenesis. Whilst partial KD enhanced adipocyte differentiation, near-total KD impaired lipid accumulation and adipogenic gene expression. Over-expression of TCF7L2 accelerated adipogenesis. In contrast, TCF7L2-KD in gluteal APs dose-dependently enhanced lipid accumulation. Transcriptome-wide profiling revealed that TCF7L2 might modulate multiple aspects of AP biology including extracellular matrix secretion, immune signaling and apoptosis. The T2D-risk allele at rs7903146 was associated with reduced AP TCF7L2 expression and enhanced AT insulin sensitivity. CONCLUSIONS: TCF7L2 plays a complex role in AP biology and has both dose- and depot-dependent effects on adipogenesis. In addition to regulating pancreatic insulin secretion, genetic variation at TCF7L2 might also influence T2D risk by modulating AP function. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Verma, Manu AU - Verma M AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. FAU - Loh, Nellie Y AU - Loh NY AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. FAU - Sabaratnam, Rugivan AU - Sabaratnam R AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK; Steno Diabetes Center Odense, Odense University Hospital, DK-5000 Odense, Denmark; Department of Clinical Research, University of Southern Denmark, DK-5000 Odense, Denmark. FAU - Vasan, Senthil K AU - Vasan SK AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. FAU - van Dam, Andrea D AU - van Dam AD AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. FAU - Todorcevic, Marijana AU - Todorcevic M AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. FAU - Neville, Matthew J AU - Neville MJ AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. FAU - Toledo, Enrique AU - Toledo E AD - Department of Computational Biology, Novo Nordisk Research Centre Oxford, UK. FAU - Karpe, Fredrik AU - Karpe F AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, OUH Foundation Trust, Oxford OX3 7LE, UK. FAU - Christodoulides, Constantinos AU - Christodoulides C AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, OUH Foundation Trust, Oxford OX3 7LE, UK. Electronic address: costas.christodoulides@ocdem.ox.ac.uk. LA - eng GR - FS/16/45/32359/BHF_/British Heart Foundation/United Kingdom GR - RG/17/1/32663/BHF_/British Heart Foundation/United Kingdom PT - Journal Article DEP - 20220610 PL - United States TA - Metabolism JT - Metabolism: clinical and experimental JID - 0375267 RN - 0 (TCF7L2 protein, human) RN - 0 (Transcription Factor 7-Like 2 Protein) SB - IM MH - *Adipose Tissue/cytology/metabolism MH - *Diabetes Mellitus, Type 2/genetics/metabolism MH - Endothelial Cells/metabolism MH - Genetic Predisposition to Disease MH - Humans MH - Lipid Metabolism MH - *Transcription Factor 7-Like 2 Protein/genetics/metabolism OTO - NOTNLM OT - Adipogenesis OT - Adipose OT - Human OT - TCF7L2 OT - Type 2 diabetes OT - WNT EDAT- 2022/06/14 06:00 MHDA- 2022/07/08 06:00 CRDT- 2022/06/13 19:32 PHST- 2021/10/26 00:00 [received] PHST- 2022/05/31 00:00 [revised] PHST- 2022/06/04 00:00 [accepted] PHST- 2022/06/14 06:00 [pubmed] PHST- 2022/07/08 06:00 [medline] PHST- 2022/06/13 19:32 [entrez] AID - S0026-0495(22)00118-4 [pii] AID - 10.1016/j.metabol.2022.155240 [doi] PST - ppublish SO - Metabolism. 2022 Aug;133:155240. doi: 10.1016/j.metabol.2022.155240. Epub 2022 Jun 10.